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Background. Allergic diseases impair health-related quality of life (HR-QoL). However, the relationship between airway inflam-
mation and HR-QoL in patients with asthma and rhinitis has not been fully investigated. We explored whether the inflammation
of upper and lower airways is associated with HR-QoL. Methods. Twenty-two mild allergic asthmatics with concomitant rhinitis
(10 males, 38 ± 17 years) were recruited. The Rhinasthma was used to identify HR-QoL, and the Asthma Control Test (ACT) was
used to assess asthma control. Subjects underwent lung function and exhaled nitric oxide (eNO) test, collection of exhaled breath
condensate (EBC), and nasal wash. Results.The Rhinasthma Global Summary score (GS) was 25 ± 11. No relationships were found
between GS and markers of nasal allergic inflammation (% eosinophils: 𝑟 = 0.34, 𝑃 = 0.24; ECP: 𝑟 = 0.06, 𝑃 = 0.87) or bronchial
inflammation (pHof the EBC: 𝑟 = 0.12,𝑃 = 0.44; bronchialNO: 𝑟 = 0.27,𝑃 = 0.22; alveolarNO: 𝑟 = 0.38,𝑃 = 0.10).ThemeanACT
score was 18. When subjects were divided into controlled (ACT ≥ 20) and uncontrolled (ACT < 20), the alveolar NO significantly
correlated with GS in uncontrolled asthmatics (𝑟 = 0.60, 𝑃 = 0.04). Conclusions. Upper and lower airways inflammation appears
unrelated to HR-QoL associated with respiratory symptoms. These preliminary findings suggest that, in uncontrolled asthma,
peripheral airway inflammation could be responsible for impaired HR-QoL.
1. Background
Asthma is one of the most common chronic diseases in the
world and is associated with high morbidity, decreased pro-
ductivity, poorer quality of life, and higher health care costs.
According to the Global Initiative for Asthma (GINA) guide-
lines [1], the goal of asthma therapy is to achieve andmaintain
full control over the disease. Clinical manifestations of
asthma can be controlledwith appropriate anti-inflammatory
treatment. When asthma is controlled, there should be no
more than occasional flare-ups. Moreover, it would be desir-
able to accomplish full asthma control using the minimum
possible number of drugs to reduce the likelihood of side
effects. In other words, the goal of GINA guidelines is the
return to an “acceptable” health related (HR) quality of life
(QoL), with little or no impact of the disease on patient’s life.
An important factor thatmay impact on current strategies
of asthma control is the presence of associated morbidities.
Among these, rhinitis plays a prominent role [2].The associa-
tion of rhinitis and asthmatic symptoms reduces performance
at school andwork, affects learning, andworsens the quantity
and quality of sleep. For all these reasons, in recent years a
growing number of studies have focused on assessing theHR-
QoL benefits that medical care can provide to patients with
asthma and associated conditions [3, 4]. Several studies have
demonstrated a correlation between the severity of rhinitic
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and asthmatic symptoms, as well as the impact of associated
rhinitis on asthma severity [2, 5–7]. In addition, allergic
rhinitis and asthma have been demonstrated to interfere with
HR-QoL [4, 7, 8]. However, to what extent the severity of
upper and lower inflammation affects HR-QoL in patients
with asthma and rhinitis has not been investigated so far.The
current study aimed at exploringwhetherHR-QoLof patients
with respiratory allergy diseases is associated with inflamma-
tory changes in the upper and lower airways. Therefore, it is
intended as preliminary to larger, more specifically tailored
studies.
2. Methods
2.1. Patients. The study was conducted at the Department of
Biomedicine and Internal Medicine, Section of Pneumology,
University of Palermo upon approval from the local research
ethics committee. We recruited subjects with bronchial
asthma and concomitant allergic rhinitis, on the basis of
clinical assessment and skin reactivity to common allergens.
The diagnosis of asthma was based on the presence of res-
piratory symptoms such as cough, chest tightness, wheezing,
acute episodes of dyspnea, and the ascertainment of variable
airway obstruction by chest examination and spirometry, in
agreement with the GINA guidelines [1]. Allergic rhinitis was
diagnosed by the presence of recurrent episodes of runny
nose, sneezing, nasal congestion, and itching, according to
the most recent ARIA guidelines [9]. Skin prick tests were
performed on all subjects at least one week after suspension
of antihistamine therapy. Subjects enrolled in this study had
mild asthma (FEV
1
> 80% predicted) and tested positive to
at least one aeroallergen. We excluded patients with heart
disease and/or uncontrolled chronic liver disease and cancer,
both past and current.
2.2. StudyDesign. The studywas performed in one visit. Each
patient underwent a clinical evaluation and the administra-
tion of questionnaires on HR-QoL assessment (Rhinasthma)
and the degree of disease control (Asthma Control Test,
ACT). Subjects were refrained from taking medications the
two weeks preceding the study day, with the exception of
rescue medications. Each patient also underwent the fol-
lowing functional and biological investigations: respiratory
function test, measurement of exhaled nitric oxide (eNO),
collection of exhaled breath condensate (EBC), and nasal
wash. Short-acting beta-agonists were stopped the day before
the tests. The study was performed in accordance with
the Good Clinical Practice guidelines recommended by the
International Conference on Harmonization of Technical
Requirements and was approved by the Ethics Committee
of University Hospital of Palermo, and all participants gave
written informed consent before inclusion. Allmeasurements
took place in the morning, and coffee or tea was not allowed
prior to the evaluation.
2.2.1. Clinical Investigations. The Rhinasthma questionnaire
assesses the impact of rhinitis and asthma on the patient’s
HR-QoL. This questionnaire is composed of 30 questions,
whose responses are graded based on the subject’s perception
of symptoms and converted into a 0–100 score to allow a
quantitative estimate of the QoL associated with disease of
the upper airways (UA) or lower airways (LA) and the impact
of allergic symptoms over the QoL (Rhinitis-Asthma Impact
(RAI)). Moreover, Rhinasthma provides a global summary
(GS) that indicates the overall impact of symptoms over the
patient’s QoL [8].
Each patient was also administered the ACT question-
naire which allows the estimate of the level of asthma control.
The test consists of five questions. The resulting ACT score
is interpreted as follows: fully controlled asthma (score ≥
25), poorly to partially controlled asthma (score 20–24), or
uncontrolled asthma (score < 20) [10]. The questions address
symptoms and rescue medication use occurring within the 4
weeks preceding the evaluation.
2.2.2. Functional Investigations. Respiratory function was
assessed through a bell-shaped spirometer, in line with the
most recent guidelines of the ATS/ERS recommendations
[11]. We recorded, in addition to FEV
1
, FVC, and FEV
1
/FVC,
also the expiratory flows at different lung volumes (FEF
25%,
FEF
50%, FEF75%, and FEF25−75%). Lung function was defined
as normal when FEV
1
/FVC was above 88% of predicted
(lower limit of normality).
2.2.3. Biological Investigations. This evaluation aimed at as-
sessing the inflammatory profile of lower and upper airways
by employing nitric oxide (NO)measurements in the expired
air, exhaled breath condensate (EBC), and nasal wash.
The fraction of exhaled NO (FENO) wasmeasured with a
standardized single-breathmethod by using the electrochem-
ical analyzer (HypAir FeNO, Medisoft), which was calibrated
daily.Themeasurement procedurewas consistent with guide-
lines published by the American Thoracic Society/European
Respiratory Society [12]. Subjects were in sitting position
during the entire procedure. Each individual was asked to
take a deep inspiration from room air and, immediately
after, to forcefully exhale through the mouthpiece that was
connected to the online analyzer. To determine if subjects
maintained a constant flow-rate during exhalation, a contin-
uous monitoring of expiratory flow rate by graphic display
on the monitor screen was used. All samples were acquired
in the morning between 11:00 and 12:00. FENO was obtained
as the mean of three acceptable measurements at the airflow
rate of 50mL/s. The alveolar concentration of NO (Calv)
was calculated by using multiple exhalation flow rates of 50,
150, 250, and 350mL/s. Calv is described by the slope of the
plotting of the expiration rates of NO against the exhalation
airflow. No correction formula was applied, since this is still
a matter of debate.
EBC was collected using a condenser (EcoScreen; Jaeger;
Wurzburg, Germany) [13]. Patients were asked to clean the
oral cavity before and during operation to reduce contami-
nation of the sample with saliva. The subjects were asked to
breathe at tidal volume, with a normal frequency, through a
mouthpiece connected to a two-way valve with saliva trap,
wearing a nose clip for about 10 minutes. The condensate,
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whose quantity varied between 1 and about 4mL, was col-
lected on ice at −20∘C, aliquoted, and transferred immedi-
ately at −80∘C.The samples were analyzed within one month
of collection. The pH of these samples was measured with
a pH meter (HI 221, HANNA Instruments) equipped with a
microelectrode after deaeration with argon (350mL/min) for
5 minutes to remove carbon dioxide.
Nasal washes were performed by instilling 5mL of Ringer
solution, preheated at 37∘C, in each nostril through a sterile
syringe. During the procedure the patient sits with head tilted
back at 30 degrees horizontally and occludes the nasopharynx
with the soft palate, then tilts his head forward and forces the
liquid into a sterile test tube. The volume of liquid obtained
was measured using a graduated container, then the sample
was stirred and filtered through a Cell Strainer (70𝜇mmesh,
BD Falcon) to remove mucus and centrifuged at 1600 rpm
at 4∘C for 20 minutes. The supernatant was stored at −80∘C
for subsequent determination of eosinophil cationic protein
(ECP), while the cellular pellet was resuspended in 0.3mL
of PBS. An aliquot (20 𝜇L) of this suspension was applied
onto a Burker chamber for the total cellular count, then
equivalent numbers of cells were cytospun onto slides for
differential cell count (Shandon) at 500 rpm for 5 minutes,
allowed to dry, and stained with Diff-Quick. Slides were
observed at the optical microscope by two different operators
in order to verify the reproducibility of the data. At least
100 cells were enumerated in 3 different sites or 6 random
fields. ECP concentration was measured in supernatants by
chemiluminescence using an IMMULITE 2000 instrument
as described. ECP concentration is expressed as ng/mL. The
limit of the assay is 200 ng/mL.
2.2.4. Statistical Analyses. Due to the explorative nature of
the study, no formal sample size calculation was performed.
Depending on the distribution of the variables, nonparamet-
ric tests were usedwhenever appropriate. Data are reported as
mean ± SD. Nonparametric tests were used for nonnormally
distributed variables. Unpaired 𝑡-test was used to compare
variables from different groups. Linear regression slopes or
Spearman rank correlations were constructed to assess the
relationships between variables. In all analyses, two-tailed 𝑃
values ≤ 0.05 were considered statistically significant. The
statistical package we employed was StatView 5.0.1 (Abacus
Concept, Berkeley, CA, USA).
3. Results
Twenty-five consecutive asthmatics were recruited. After
enrollment, three subjects refused to participate for reasons
not related to the nature of the study. A total of twenty-two
subjects took part in the study (M/F: 10/12, age: 38 ± 17 yrs,
mean± SD).TheGS score of Rhinasthmawas 25± 11, ranging
between 7.5 and 47.5. Figure 1 also depicts the mean ± SD
values of single domains (UA, LA, and RAI). All patients
showed values of respiratory function within a normal range
(FEV
1
/FVC% predicted above 88%, LLN). FEV
1
% predicted
ranged from 82 to 129%, and FVC% predicted ranged from
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Figure 1: Values for (single) domains of the Rhinasthma question-
naire. GS: Global Summary score; UA: upper airway score; LA: lower
airway score; RAI: rhinitis-asthma impact score.
Table 1: Lung function characteristics of the study subjects.
FEV1, % predicted 99 ± 21
FVC, % predicted 107 ± 19
FEV1/FVC, % predicted 98 ± 8
FEF25, % predicted 74 ± 33
FEF50, % predicted 87 ± 35
FEF75, % predicted 88 ± 26
FEF25–75, % predicted 80 ± 32
Table 2: Inflammatory markers from upper and lower airways.
FENO, ppb 21 ± 19
Alveolar NO, ppb 6.9 ± 5.9
pH of EBC 6.81 ± 0.1
ECP, ng/mL (nasal wash) 4.89 ± 3.4
Eosinophils, % (nasal wash) 13.5 ± 8.7
Neutrophils, % (nasal wash) 56 ± 21.9
Macrophages, % (nasal wash) 19.2 ± 19.2
Lymphocytes, % (nasal wash) 8.6 ± 5.1
EBC: exhaled breath condensate; ECP: eosinophil cationic protein.
83 to 129%. Complete baseline lung function measures of the
study subjects are presented in Table 1.
The biological findings from upper and lower airway
procedures are described in Table 2. With regard to the NO
values, the FENO values were around the upper normal level
of eNO, which ranges from 20 to 30 ppb, with 95th percentile
values being 39 ppb for subjects 12 to 80 years of age. On
the other hand, no reference values are still available for
the alveolar concentrations. The pH of the EBC was lower
than that usually recorded in healthy subjects, suggesting
a condition of airway inflammation. The detection of ECP
levels and eosinophils in the nasal wash also confirm the
occurrence of allergic inflammation in the upper airways.We
also assessed the level of asthma control: themean ACT score
was 18; in detail, 3 patients had a totally controlled asthma
(ACT = 25), 6 partially controlled (20 ≤ ACT < 24), and 13
uncontrolled (ACT < 20).
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Figure 2: Correlation between the Rhinasthma total score and the
Asthma Control Test score.
As expected, we found a significant correlation between
the Rhinasthma GS score and the ACT score (𝑟2 = 0.34, 𝑃 =
0.005) (Figure 2). In addition, Rhinasthma LA (𝑟2 = 0.37,𝑃 =
0.003) (Figure 3(a)) but not UA (𝑟2 = 0.09, 𝑃 = 0.17) and
RAI (𝑟2 = 0.08, 𝑃 = 0.20) (Figures 3(b) and 3(c)) correlated
significantly with the ACT score.
To assess whether the HR-QoL is affected by the degree of
upper and lower airway inflammation, we explored possible
correlations between these measures through simple regres-
sion analysis. The Rhinasthma GS did not correlate with the
percent of eosinophils (𝑟2 = 0.11, 𝑃 = 0.24), or with ECP
levels (𝑟2 = 0.004, 𝑃 = 0.87) in the nasal wash. Likewise, we
found no significant correlation between RhinasthmaGS and
the EBC pH (𝑟2 = 0.01, 𝑃 = 0.44). Finally, neither FeNO or
Calv values showed a significant correlation with the Rhi-
nasthma GS. Similar results were obtained for the single
domains of Rhinasthma (UA, LA, and RAI).
To further investigate the role of airway inflammation on
the HR-QoL of patients with asthma, we divided them into
two groups according to the level of disease control: group 1
(patients with fully or partially controlled asthma, ACT ≥ 20)
and group 2 (patients with uncontrolled asthma, ACT < 20).
The two groups were similar with respect to the pulmonary
function: FEV
1
was, respectively, 105 ± 18% and 95 ± 22% of
predicted value, 𝑃 = 0.26; FVC was 116 ± 20% and 101 ± 17%,
𝑃 = 0.07. Similarly, the expiratory flow rates at various lung
volumes did not differ significantly between the two groups
(𝑃 > 0.05 in all cases). With regard to the inflammatory
markers in the nasal washes, no significant differences were
found between groups 1 and 2 in eosinophil percentages (15 ±
9.8% versus 13 ± 8%, respectively; 𝑃 = 0.67) and ECP con-
centrations (5.8 ± 3.2 ng/mL versus 3.9 ± 3.6 ng/mL, respec-
tively; 𝑃 = 0.42). The pH of EBC was, respectively, 6.85 ±
0.16 and 6.79 ± 0.20 (𝑃 = 0.49). FeNO levels were not signif-
icantly different between the two groups (16 ± 5.3 ppb versus
25 ± 23 ppb, respectively; 𝑃 = 0.26). In contrast, Calv was
threefold higher in patients with uncontrolled asthma (9 ±
6.5 ppb) than in those with totally or partially controlled
asthma (3 ± 2.3 ppb) (𝑃 = 0.01). In addition, a significant
correlation between Rhinasthma GS and Calv was found in
patients with uncontrolled asthma (𝑟 = 0.60, 𝑃 = 0.04)
(Figure 4).
4. Discussion
The results of this pilot study suggest that, in individuals
with uncontrolled asthma, the HR-QoL is associated with
inflammatory changes in the peripheral airways.The findings
of the current study could carry clinical implications. In
our previous study [14], we demonstrated that the improved
control of respiratory symptoms obtained with nasal corti-
costeroids in allergic rhinitics with asthma appeared to be
mediated by functional changes in the peripheral airways. It
is plausible to speculate that, in individuals with uncontrolled
asthma, a more intensive anti-inflammatory treatment, per-
haps targeting the small airways, is necessary to improve HR-
QoL.
The main limitation of the study is represented by the
small number of subjects. This implies that no generalization
of the findings can be applied to the asthmatic population.
The small number of subject could explain the lack of
significance between biological variables and quality of life.
It is, however, important to highlight that the study was
exploratory in nature and was intended as preliminary to
larger studies with the attempt to select those biological
markerswho could show an associationwith impaired quality
of life. In addition, we did not measure nasal NO; we feel
confident, however, that ECP in the nasal wash provides
similar information on the quality and magnitude of nasal
inflammation. In addition, the discrepancy between normal
lung function and lack of asthma control is only apparent;
indeed, the control of asthma, specifically the ACT, which
reflects the patient’s perception of disease control, can be
dissociated from the level of airway obstruction measured by
the physician.
The importance of measuring QoL in chronic allergic
respiratory patients lies in the notion that the different
pathophysiologic parameters that are commonly used as an
index of severity are only part of a more general state of
health. In addition to the common functional and clinical
manifestations of asthma and rhinitis, these two conditions
are typically associated with fatigue, disturbed sleep, and
discomfort from therapies and medical equipment [4]. It is
well known that asthma can cause a host of psychological
problems such as anxiety, fear, addiction, or depression [15].
Rhinitis reduces academic and work performance, affects
learning, and reduces the quantity and quality of sleep [16].
This stresses the need to assess the QoL of these patients
by administration of specific instruments, for example, ques-
tionnaires. To this aim, we administered the Rhinasthma
questionnaire, in which asthma and rhinitis are considered
as different manifestations of the same disease [17].
Evaluation of NO in exhaled air has been proposed not
only as a new experimental tool in translational medicine
but also as a valuable clinical resource for asthma screening,
diagnosis, and monitoring [18, 19]. Hence, its measurement
could be used to assess asthma severity and the risk for
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Figure 3: Correlations between the Asthma Control Test and Rhinasthma LA (a), UA (b), and RAI (c). LA: lower airway score; UA: upper
airway score; RAI: rhinitis-asthma impact score.
50
45
40
35
30
25
20
15
10
5
0
Rh
in
as
th
m
a (
G
S)
Alveolar NO (ppb)
0 5 10 15 20 25 30
r = 0.25
P = 0.54
(a) Controlled asthma
50
45
40
35
30
25
20
15
10
5
0
Rh
in
as
th
m
a (
G
S)
Alveolar NO (ppb)
0 5 10 15 20 25 30
r = 0.60
P = 0.04
(b) Uncontrolled asthma
Figure 4: Correlations between the Rhinasthma global score and alveolar NO in controlled (a) and uncontrolled (b) asthmatics.
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exacerbations in asthmatic patients. In recent years, several
studies have been performed to evaluate the relationship
between eNO levels and parameters of lung function or other
markers of airway inflammation [20]. In particular, it is well
established that alveolar eNO levels are representative of
peripheral bronchial inflammation [21–23]. As also inferred
in several studies, the peripheral airways in asthmatics are
the site of an inflammatory infiltrate that is not observed in
nonasthmatic controls and, within asthmatic lungs, is more
intense than in the central airways [24, 25].
In conclusion, the results of our explorative study provide
additional insights into the factors that affect asthma control
and the QoL associated with symptoms of upper and lower
respiratory allergic diseases, suggesting amajor role of abnor-
malities at the level of peripheral airways. Although novel,
the findings of the current study should be interpreted with
caution and confirmed by further studies specifically aiming
at addressing the role of peripheral airways in impaired
quality of life of uncontrolled asthmatics. We emphasize
the need to perform the alveolar NO methodology to test
whether in large population of uncontrolled asthmatics small
airway abnormalities are the cause of impaired quality of life.
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